Greg Grove, partner in the firm's Corporate & Securities practice group, was recently quoted in the Investor's Business Daily article "The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree." In the article, he highlights the potential ramifications that could arise from potential FTC regulatory changes and how they might affect the industry's growth trajectory.

Read the article here.